	Subt. Form P	ORMATION	DISCLO	SURE	Docket Number 47508-556 (HYZ-069CN2)	Application Number 09/896,692		
FEB	 	IN AN APP e several she			Applicant Agrawal			
STEW	a restress	1	OF		Filing Date June 29, 2001	Group Art Unit 1635		
-	a INNO	'	1 1		, , , , , , , , , , , , , , , , , , , ,			

		U.	S. Patent Docume	nts		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE JP APPROPRIATE
93	4,806,463	05/1986	Goodchild et al.	435	5	
09	5,470,702	01/1993	Hovanessian et al.	435	5/	
	5,591,721	10/1994	Agrawal et al.	514	44	
	5,652,355	07/1997	Metelev et al.	536	24.5	
	5,652,356	07/1997	Agrawai	536	24.5	
	6,608,035	08/2003	Agrawal et al.	5/4	44	
1	6,645,943	11/2003	Agrawal et al.	/514	44-	

		Fore	ign Patent Docum	nents			
EXAMINER	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL		DATE	COUNTRY			YES	NO
(15)	WO96/12497	05/02/96	PCT				
7119	WO 98/40058	9/17/1998	PCT				
V.							
	:						

	Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)					
)2 A1	Agrawal, et al. (1992) "GEM*91 – An Antisense Oligonucleotide Phosphorothioate as a Therapeutic Agent for AIDS", Antisense Res. Dev. 2:261-266					
V 9 A2	Agrawal et al. (1994) "Potential for HIV-1 Treatment with Antisense Oligonucleotides", J. Biotech. in Healthcare, 1(2):167-182.					
A3	Agrawal, et al. (1995) "Pharmacokinetics of Antisense Oligonucleotides", Clin. Pharmacokinet. 28(1):7-16					
A4	Agrawal (1996) "Preface" In Methods in Molecular Medicine: Antisense Therapeutics (Agrawal,ed.) pp. v-vii					
A5	Agrawal, et al. (1998) "Pharmacokinetics and Bioavailability of Antisense Oligonucleotides Following Oral and Colorectal Administrations in Experimental Animals", in <u>Handbook of Experimental Pharmacology</u> , Vol. 131: Antisense Research and Application, Springer-Verlag, pp. 525-543					
A6	Agreeval (1999) "Importance of Nucleotide Sequence and Chemical Modifications of Antisense Olinonucleotides."					
A7	A7 Beaucage (1993) "Oligodeoxyribonucleotides Synthesis" In Methods in Molecular Biology, Vol. 20: Protocols for Oligonucleotides and Analogs, (Agrawal, ed.) Humana Press, Totowa, NJ, pp.33-61					
A8	Brown (1993) "A Brief History of Oligonucleotide Synthesis" in Methods in Malecular Biology, Vol. 20: Protocols for Oligonucleotides and Analogs, "pp. 1-17					
A9	A9 Craig et al. (1997) "Patent strategies in the antisense oligonucleotide based therapeutic approach" Exp. Opin. Ther. Patents 7(10):1175-1182					
A10	Database CAS Registry (2003), (Date of entry: 1997), Registry number 193635-63-1					
A11 Froehler (1993) "Oligodeoxynucleotide Synthesis," Methods in Molecular Biology, Vol. 20; Protocols Oligonucleotides and Analogs (Agrawal, ed.) Humana Press, Towtowa, NJ, pp. 63-80						
A12	Furdon (1989) "RNase II cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds," Nucleic Acids Research, Vol. 17:22, pp. 9193-9205					
¥ A13	Galderisi et al. (1999) "Antisense Oligonucleotides as Therapeultic Agents" J. Cell. Physiol. 181:251-257					
EXAMINER	DATE CONSIDERED ,					
	10/10/04					
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation						
if not conforms	ance and not considered. Include copy with next communication to applicant.					

Subt. Form P	FO-1449	Docket Number	Application Number		
		47508-556	09/896,692		
- HAR	ORMATION DISCLOSURE	(HYZ-069CN2)	\sim		
01rE	IN AN APPLICATION	Applic	ant		
FEB 0 4 500	se several sheets if necessary)	Agra	Ch (0)		
- 4 7 200) #	Filing Date	Group Art Und		
Sheet .	2 OF 2	June 29, 2001	1635		
Sheet			47/		
3 A14	Ongonucieotides: An ili vitro Model for Treati	ment", Proc. Natl. Acad. Sci. USA 89:1	1209-11213		
0 A15	Oligonucieotide Phosphorothioates*, Proc. Na	atl. Acad. Sci. USA 90:3860-3864			
A16	91:7942-7946	s Type 1 in Human Peripheral Blood C	ells", Proc. Natl. Acad. Sci. USA		
A17	Liss, Inc., pp. 159-178	se Nucleic Acid Therapy of Cancer and	AIDS (Wickstrom, ed.), Wiley-		
A18	1 ADSTRACTS, 128(13):272				
A19	1 <i>Chemistry</i> , 23(9):6/3-6//, Translated from Di	loorganicheskaya Khimiya 23(9):742-7	46		
A20	Milligan, et al. (1993) "Current Concepts in Ar 1937 Milner et al. (1997) "Selecting Effective Antise	-			
A21	Biotech. 15:537-541 Palu, G., et al. (1999) "In Pursuit of new deve	-			
A22	Biotechnology, 68:1-13	·			
A23		ntides: A New Therapeutic Principle." (Chem. Rev. 90(4):543-584		
A25	Zamecnik (1996) "History of Antisense Oligor (Agrawal.ed.) Humana Press, Totowa, NJ, pp	nucleotides" in <u>Methods in Molecular N</u> p. 1-11	ledicine: Antisense Therapeutics		
A26	Zhang et al. (1995) "In Vivo Stability, Disposition and Metabolism of a "Hybrid" Oligonucleotide Phosphorothioate i Rats." Biochem. Pharmacol. 50(4): 545-556				
A27	ntisense Oligodeoxynucleotide):44-53.				
A28	Therapeutics 278(2):971-979	Administration," Journal of Pharmacolo	gy and Experimental		
√ A29	e Oligodeoxynucleotide is hemistry Letters, 10:1051-1054				
					
					
EXAMINER		DATE CONSIDERED	/		
EAAMINEM) 2	DATE CONSIDERED	1011		
,		10/	1,104		

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

BOSTON BOSTON 1822760v1